Differences in the management and survival of metastatic colorectal cancer in Europe. A population-based study
The management regarding metastatic colorectal cancer throughout Europe is not well known. To draw a European comparison of the management and prognosis of metastatic colorectal cancers. Factors associated with chemotherapy administration were identified through logistic regressions. Net survival wa...
Gespeichert in:
Veröffentlicht in: | Digestive and liver disease 2021-05, Vol.53 (5), p.639-645 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The management regarding metastatic colorectal cancer throughout Europe is not well known.
To draw a European comparison of the management and prognosis of metastatic colorectal cancers.
Factors associated with chemotherapy administration were identified through logistic regressions. Net survival was estimated and crude probabilities of death related to cancer and other causes using a flexible cumulative hazard model.
Among the 13 227 patients with colorectal cancer diagnosed between 2010 and 2013 in cancer registries from 10 European countries, 3140 were metastatic. 62% of metastatic patients received chemotherapy. Compared to Spain, the related adjusted odds ratios ranged from 0.7 to 4.0 (P |
---|---|
ISSN: | 1590-8658 1878-3562 |
DOI: | 10.1016/j.dld.2021.01.021 |